Date: 2016-10-04
Type of information: Grant
Company: SkylineDx (USA - CA - The Netherlands) Erasmus MC (The Netherlands) Myeloma Patients Europe (Belgium), University of Turin (Italy) the Institute for Medical Technology Assessment (The Netherlands)
Investors: European Commission’s Horizon 2020 programme
Amount: multi-million €
Funding type: grant
Planned used: The Horizon2020 grant from the European Commission will be used to develop a new, and novel gene-expression profiling technology, which is intended to predict the most effective treatment strategy for patients with multiple myeloma.
SkylineDx has also developed and is currently offering MMprofiler with SKY92, a gene expression-based risk identification signature that determines the level of risk for patients with multiple myeloma by classifying them into a “high” or “standard” risk group. The performance of the SKY92 gene signature to risk stratify these patients exceeds that of standard clinical parameters that include FISH, and earlier gene expression signatures utilized in myeloma.1-2 Research will be conducted to expand MMprofiler technology to include the prediction of treatment effectiveness in individual patients based on Gene Expression Profiling (GEP).
Others: * On October 4, 2016, SkylineDx announced it has been awarded a multi-million euro Horizon2020 grant from the European Commission to develop a new, and novel gene-expression profiling technology, which is intended to predict the most effective treatment strategy for patients with multiple myeloma. The consortium of European partners includes Erasmus MC (EMC, Rotterdam), Myeloma Patients Europe (MPE, Brussels), University of Turin (Unito, Turin) and the Institute for Medical Technology Assessment (iMTA, Rotterdam). The announcement comes as SkylineDx prepares for their sponsorship and support at the European School of Haematology’s 3rd International Conference on Multiple Myeloma in Milan, Italy on October 7-9, 2016.
Therapeutic area: Cancer - Oncology - Diagnostic
